Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00385450 · ClinicalTrials.gov registry record · Phase 1
Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00385450: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT00385450 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00385450, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
In previous studies, 90% of patients who underwent elective cardiopulmonary bypass procedure manifested CD4 counts of less than 500 cells/microliter in the immediate (day 1) post-operative period. This study will investigate whether or not Nelfinavir increases those CD4 counts in the post-operative period.
Interventions
- DRUG Nelfinavir/placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00385450
The ClinicalTrials.gov registry entry for NCT00385450 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nelfinavir/placebo is the first listed.
NCT00385450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00385450 about?
NCT00385450 is a clinical study titled "Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor". In previous studies, 90% of patients who underwent elective cardiopulmonary bypass procedure manifested CD4 counts of less than 500 cells/microliter in the immediate (day 1) post-operative period. This study will investigate whether or not Nelfinavir increases those CD4 counts in the post-operative ...
What is the current status of trial NCT00385450?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2006-10. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00385450?
The interventions under investigation include: Nelfinavir/placebo (DRUG).
Who is sponsoring clinical trial NCT00385450?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.